Cargando…
Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer?
SIMPLE SUMMARY: Hepatocellular carcinoma has a clear male predominance, but gender-specific differences remain incompletely understood. Our findings look specifically at the Louisiana population, which has some of the highest rates of hepatitis, alcoholic liver disease, and metabolic syndrome—thus p...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251901/ https://www.ncbi.nlm.nih.gov/pubmed/37296854 http://dx.doi.org/10.3390/cancers15112892 |
_version_ | 1785056042806149120 |
---|---|
author | Fa, Andrea Danos, Denise M. Maniscalco, Lauren Yi, Yong Wu, Xiao-Cheng Maluccio, Mary A. Chu, Quyen D. Lyons, John M. |
author_facet | Fa, Andrea Danos, Denise M. Maniscalco, Lauren Yi, Yong Wu, Xiao-Cheng Maluccio, Mary A. Chu, Quyen D. Lyons, John M. |
author_sort | Fa, Andrea |
collection | PubMed |
description | SIMPLE SUMMARY: Hepatocellular carcinoma has a clear male predominance, but gender-specific differences remain incompletely understood. Our findings look specifically at the Louisiana population, which has some of the highest rates of hepatitis, alcoholic liver disease, and metabolic syndrome—thus providing important data to better evaluate HCC trends. Our findings help illustrate specific gender differences in this disease, which remains one of the leading causes of cancer-related deaths worldwide. ABSTRACT: Hepatocellular carcinoma (HCC) is a male-dominated disease. Currently, gender differences remain incompletely defined. Data from the state tumor registry were used to investigate differences in demographics, comorbidities, treatment patterns, and cancer-specific survival (HSS) among HCC patients according to gender. Additional analyses were performed to evaluate racial differences among women with HCC. 2627 patients with HCC were included; 498 (19%) were women. Women were mostly white (58%) or African American (39%)—only 3.8% were of another or unknown race. Women were older (65.1 vs. 61.3 years), more obese (33.7% vs. 24.2%), and diagnosed at an earlier stage (31.7% vs. 28.4%) than men. Women had a lower incidence of liver associated comorbidities (36.1% vs. 43%), and more often underwent liver-directed surgery (LDS; 27.5% vs. 22%). When controlling for LDS, no survival differences were observed between genders. African American women had similar HSS rates compared to white women (HR 1.14 (0.91,1.41), p = 0.239) despite having different residential and treatment geographical distributions. African American race and age >65 were predictive for worse HSS in men, but not in women. Overall, women with HCC undergo more treatment options—likely because of the earlier stage of the cancer and/or less severe underlying liver disease. However, when controlling for similar stages and treatments, HCC treatment outcomes were similar between men and women. African American race did not appear to influence outcomes among women with HCC as it did in men. |
format | Online Article Text |
id | pubmed-10251901 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102519012023-06-10 Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? Fa, Andrea Danos, Denise M. Maniscalco, Lauren Yi, Yong Wu, Xiao-Cheng Maluccio, Mary A. Chu, Quyen D. Lyons, John M. Cancers (Basel) Article SIMPLE SUMMARY: Hepatocellular carcinoma has a clear male predominance, but gender-specific differences remain incompletely understood. Our findings look specifically at the Louisiana population, which has some of the highest rates of hepatitis, alcoholic liver disease, and metabolic syndrome—thus providing important data to better evaluate HCC trends. Our findings help illustrate specific gender differences in this disease, which remains one of the leading causes of cancer-related deaths worldwide. ABSTRACT: Hepatocellular carcinoma (HCC) is a male-dominated disease. Currently, gender differences remain incompletely defined. Data from the state tumor registry were used to investigate differences in demographics, comorbidities, treatment patterns, and cancer-specific survival (HSS) among HCC patients according to gender. Additional analyses were performed to evaluate racial differences among women with HCC. 2627 patients with HCC were included; 498 (19%) were women. Women were mostly white (58%) or African American (39%)—only 3.8% were of another or unknown race. Women were older (65.1 vs. 61.3 years), more obese (33.7% vs. 24.2%), and diagnosed at an earlier stage (31.7% vs. 28.4%) than men. Women had a lower incidence of liver associated comorbidities (36.1% vs. 43%), and more often underwent liver-directed surgery (LDS; 27.5% vs. 22%). When controlling for LDS, no survival differences were observed between genders. African American women had similar HSS rates compared to white women (HR 1.14 (0.91,1.41), p = 0.239) despite having different residential and treatment geographical distributions. African American race and age >65 were predictive for worse HSS in men, but not in women. Overall, women with HCC undergo more treatment options—likely because of the earlier stage of the cancer and/or less severe underlying liver disease. However, when controlling for similar stages and treatments, HCC treatment outcomes were similar between men and women. African American race did not appear to influence outcomes among women with HCC as it did in men. MDPI 2023-05-24 /pmc/articles/PMC10251901/ /pubmed/37296854 http://dx.doi.org/10.3390/cancers15112892 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Fa, Andrea Danos, Denise M. Maniscalco, Lauren Yi, Yong Wu, Xiao-Cheng Maluccio, Mary A. Chu, Quyen D. Lyons, John M. Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title | Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title_full | Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title_fullStr | Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title_full_unstemmed | Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title_short | Is There Really a Difference in Outcomes between Men and Women with Hepatocellular Cancer? |
title_sort | is there really a difference in outcomes between men and women with hepatocellular cancer? |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251901/ https://www.ncbi.nlm.nih.gov/pubmed/37296854 http://dx.doi.org/10.3390/cancers15112892 |
work_keys_str_mv | AT faandrea istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT danosdenisem istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT maniscalcolauren istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT yiyong istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT wuxiaocheng istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT malucciomarya istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT chuquyend istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer AT lyonsjohnm istherereallyadifferenceinoutcomesbetweenmenandwomenwithhepatocellularcancer |